VX-770: Phase III start

This quarter, Vertex will begin a 2-part, double-blind, international Phase III trial to evaluate oral VX-770 in patients ages 6-11 carrying the G551D mutation in CFTR on at least 1 allele. The first part of the study will evaluate the pharmacokinetics of a single dose of oral VX-770 in about 10 patients. The second part of the study will compare oral VX-770 given twice daily vs. placebo for 48 weeks in about 30 patients. Patients completing the trial will have the option to enroll in an extension study. ...